Frank Ulrich Weiss1, Claudia Schurmann2, Annett Guenther1, Florian Ernst3, Alexander Teumer3, Julia Mayerle1, Peter Simon1, Henry Völzke4, Dörte Radke4, Andreas Greinacher5, Jens-Peter Kuehn6, Martin Zenker7, Uwe Völker3, Georg Homuth3, Markus M Lerch1. 1. Department of Medicine A, University Medicine Greifswald, Greifswald, Germany. 2. Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany The Charles Bronfman Institute for Personalized Medicine, Genetics of Obesity & Related Metabolic Traits Program, Icahn School of Medicine at Mount Sinai, New York, USA. 3. Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. 4. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. 5. Department of Transfusion Medicine, Institute of Immunology and Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany. 6. Department of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany. 7. Institute of Human Genetics, Otto-von-Guericke-Universität Magdeburg, University Hospital Magdeburg, Germany.
Abstract
OBJECTIVE: Serum lipase activities above the threefold upper reference limit indicate acute pancreatitis. We investigated whether high lipase activity-within the reference range and in the absence of pancreatitis-are associated with genetic single nucleotide polymorphisms (SNP), and whether these identified SNPs are also associated with clinical pancreatitis. METHODS: Genome-wide association studies (GWAS) on phenotypes 'serum lipase activity' and 'high serum lipase activity' were conducted including 3966 German volunteers from the population-based Study-of-Health-in-Pomerania (SHIP). Lead SNPs associated on a genome-wide significance level were replicated in two cohorts, 1444 blood donors and 1042 pancreatitis patients. RESULTS: Initial discovery GWAS detected SNPs within or near genes encoding the ABO blood group specifying transferases A/B (ABO), Fucosyltransferase-2 (FUT2), and Chymotrypsinogen-B2 (CTRB2), to be significantly associated with lipase activity levels in asymptomatic subjects. Replication analyses in blood donors confirmed the association of FUT-2 non-secretor status (OR=1.49; p=0.012) and ABO blood-type-B (OR=2.48; p=7.29×10(-8)) with high lipase activity levels. In pancreatitis patients, significant associations were found for FUT-2 non-secretor status (OR=1.53; p=8.56×10(-4)) and ABO-B (OR=1.69, p=1.0×10(-4)) with chronic pancreatitis, but not with acute pancreatitis. Conversely, carriers of blood group O were less frequently affected by chronic pancreatitis (OR=0.62; p=1.22×10(-05)) and less likely to have high lipase activity levels (OR=0.59; p=8.14×10(-05)). CONCLUSIONS: These are the first results indicating that ABO blood type-B as well as FUT2 non-secretor status are common population-wide risk factors for developing chronic pancreatitis. They also imply that, even within the reference range, elevated lipase activities may indicate subclinical pancreatic injury in asymptomatic subjects. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: Serum lipase activities above the threefold upper reference limit indicate acute pancreatitis. We investigated whether high lipase activity-within the reference range and in the absence of pancreatitis-are associated with genetic single nucleotide polymorphisms (SNP), and whether these identified SNPs are also associated with clinical pancreatitis. METHODS: Genome-wide association studies (GWAS) on phenotypes 'serum lipase activity' and 'high serum lipase activity' were conducted including 3966 German volunteers from the population-based Study-of-Health-in-Pomerania (SHIP). Lead SNPs associated on a genome-wide significance level were replicated in two cohorts, 1444 blood donors and 1042 pancreatitispatients. RESULTS: Initial discovery GWAS detected SNPs within or near genes encoding the ABO blood group specifying transferases A/B (ABO), Fucosyltransferase-2 (FUT2), and Chymotrypsinogen-B2 (CTRB2), to be significantly associated with lipase activity levels in asymptomatic subjects. Replication analyses in blood donors confirmed the association of FUT-2 non-secretor status (OR=1.49; p=0.012) and ABO blood-type-B (OR=2.48; p=7.29×10(-8)) with high lipase activity levels. In pancreatitispatients, significant associations were found for FUT-2 non-secretor status (OR=1.53; p=8.56×10(-4)) and ABO-B (OR=1.69, p=1.0×10(-4)) with chronic pancreatitis, but not with acute pancreatitis. Conversely, carriers of blood group O were less frequently affected by chronic pancreatitis (OR=0.62; p=1.22×10(-05)) and less likely to have high lipase activity levels (OR=0.59; p=8.14×10(-05)). CONCLUSIONS: These are the first results indicating that ABO blood type-B as well as FUT2 non-secretor status are common population-wide risk factors for developing chronic pancreatitis. They also imply that, even within the reference range, elevated lipase activities may indicate subclinical pancreatic injury in asymptomatic subjects. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Sakina H Bharmal; Sayali A Pendharkar; Ruma G Singh; Mark O Goodarzi; Stephen J Pandol; Maxim S Petrov Journal: Pancreatology Date: 2017-09-20 Impact factor: 3.996
Authors: Malte Christoph Rühlemann; Britt Marie Hermes; Corinna Bang; Shauni Doms; Lucas Moitinho-Silva; Louise Bruun Thingholm; Fabian Frost; Frauke Degenhardt; Michael Wittig; Jan Kässens; Frank Ulrich Weiss; Annette Peters; Klaus Neuhaus; Uwe Völker; Henry Völzke; Georg Homuth; Stefan Weiss; Harald Grallert; Matthias Laudes; Wolfgang Lieb; Dirk Haller; Markus M Lerch; John F Baines; Andre Franke Journal: Nat Genet Date: 2021-01-18 Impact factor: 38.330
Authors: Aliye Uc; Dana K Andersen; Melena D Bellin; Jason I Bruce; Asbjørn M Drewes; John F Engelhardt; Christopher E Forsmark; Markus M Lerch; Mark E Lowe; Brent A Neuschwander-Tetri; Stephen J OʼKeefe; Tonya M Palermo; Pankaj Pasricha; Ashok K Saluja; Vikesh K Singh; Eva M Szigethy; David C Whitcomb; Dhiraj Yadav; Darwin L Conwell Journal: Pancreas Date: 2016-11 Impact factor: 3.327
Authors: Khadija El Jellas; Bente B Johansson; Karianne Fjeld; Aristotelis Antonopoulos; Heike Immervoll; Man H Choi; Dag Hoem; Mark E Lowe; Dominique Lombardo; Pål R Njølstad; Anne Dell; Eric Mas; Stuart M Haslam; Anders Molven Journal: J Biol Chem Date: 2018-10-12 Impact factor: 5.157
Authors: Julia Mayerle; Matthias Sendler; Eszter Hegyi; Georg Beyer; Markus M Lerch; Miklós Sahin-Tóth Journal: Gastroenterology Date: 2019-01-18 Impact factor: 22.682
Authors: Sigurgeir Olafsson; Kristjan F Alexandersson; Johann G K Gizurarson; Katrin Hauksdottir; Orvar Gunnarsson; Karl Olafsson; Julius Gudmundsson; Simon N Stacey; Gardar Sveinbjornsson; Jona Saemundsdottir; Einar S Bjornsson; Sigurdur Olafsson; Sigurdur Bjornsson; Kjartan B Orvar; Arnor Vikingsson; Arni J Geirsson; Sturla Arinbjarnarson; Gyda Bjornsdottir; Thorgeir E Thorgeirsson; Snaevar Sigurdsson; Gisli H Halldorsson; Olafur T Magnusson; Gisli Masson; Hilma Holm; Ingileif Jonsdottir; Olof Sigurdardottir; Gudmundur I Eyjolfsson; Isleifur Olafsson; Patrick Sulem; Unnur Thorsteinsdottir; Thorvaldur Jonsson; Thorunn Rafnar; Daniel F Gudbjartsson; Kari Stefansson Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-30 Impact factor: 4.254